Paradigm Biopharmaceuticals Limited (PBIGF)
OTCMKTS · Delayed Price · Currency is USD
0.2300
0.00 (0.00%)
At close: Feb 10, 2026

PBIGF Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
---0.080.02
---0.080.02
Revenue Growth (YoY)
---285.52%-
Cost of Revenue
0.020.010.020.140.1
Gross Profit
-0.02-0.01-0.02-0.06-0.08
Selling, General & Admin
5.586.777.398.859.59
Research & Development
17.7458.3352.6839.0133.52
Operating Expenses
23.3265.160.0747.8743.1
Operating Income
-23.34-65.11-60.09-47.93-43.18
Interest Expense
-0.01-0.01-0.02-0.03-0.04
Interest & Investment Income
0.360.411.40.050.21
Currency Exchange Gain (Loss)
0.01-0.05-0.390.890.31
Other Non Operating Income (Expenses)
6.756.047.097.768.4
EBT Excluding Unusual Items
-16.24-58.73-52-39.25-34.3
Asset Writedown
-2.53----
Other Unusual Items
--0.09--
Pretax Income
-18.77-58.73-51.91-39.25-34.3
Net Income
-18.77-58.73-51.91-39.25-34.3
Net Income to Common
-18.77-58.73-51.91-39.25-34.3
Shares Outstanding (Basic)
315293250233230
Shares Outstanding (Diluted)
315293250233230
Shares Change (YoY)
7.23%17.43%7.34%1.21%14.32%
EPS (Basic)
-0.06-0.20-0.21-0.17-0.15
EPS (Diluted)
-0.06-0.20-0.21-0.17-0.15
Free Cash Flow
-15.99-65.94-45.19-32.21-34.96
Free Cash Flow Per Share
-0.05-0.23-0.18-0.14-0.15
Gross Margin
----81.45%-
Operating Margin
----60498.78%-210124.38%
Profit Margin
----49542.54%-166896.27%
Free Cash Flow Margin
----40650.90%-170122.95%
EBITDA
-23.19-64.97-59.93-47.74-43.13
D&A For EBITDA
0.150.150.150.190.05
EBIT
-23.34-65.11-60.09-47.93-43.18
Source: S&P Global Market Intelligence. Standard template. Financial Sources.